Yang Hong, Lu Xingqing, Qian Jiaming, Xu Fengji, Hu Yiqun, Yu Yinhua, Bast Robert C, Li Jingnan
Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China.
Mol Med Rep. 2010 Jul-Aug;3(4):581-7. doi: 10.3892/mmr_00000301.
Aplesia Ras homologue member I (ARHI, DIRAS3) is a Ras-related imprinted growth inhibitory gene whose expression is down-regulated in the majority of breast and ovarian cancers. This study investigated the inhibitory function of ARHI in pancreatic cancer. Six pancreatic cancer cell lines, tumor xenografts in nude mice and 20 pancreatic cancer tissue sections were analyzed. ARHI is widely expressed in ductal and acinar cells of normal pancreatic tissue, but is down-regulated or lost in approximately 50% of pancreatic cancers. Aberrant methylation of the ARHI locus was found in five pancreatic cancer cell lines, which exhibited down-regulation or loss of ARHI expression. Hypermethylation was detected in five cell lines (5/5, 100%) at CpG island I, in two cell lines (2/5, 40%) at CpG island II and in four cell lines (4/5, 80%) at CpG island III. Re-expression of ARHI significantly inhibited the growth of pancreatic cancer cells. This inhibition was associated with the induction of apoptosis. Treatment with the demethylating agent 5-aza-2'deoxycytidine (5-aza-dC) restored ARHI mRNA expression, inhibited cell growth and induced apoptosis in PANC-1 and P3 human pancreatic cancer cells in culture. In nu/nu mice, 5-aza-dC also inhibited the growth of PANC-1 xenografts and induced apoptosis, as observed by TUNEL staining. These effects were associated with the re-expression of ARHI protein. Therefore, ARHI may serve as a growth inhibitory gene in a significant fraction of pancreatic cancers. Re-expression of ARHI significantly induced the apoptosis of pancreatic cancer cells. A demethylation agent reduced human pancreatic cancer cell line growth in conjunction with ARHI re-expression.
Aplsia Ras同源物成员I(ARHI,DIRAS3)是一种与Ras相关的印记生长抑制基因,其表达在大多数乳腺癌和卵巢癌中下调。本研究调查了ARHI在胰腺癌中的抑制功能。分析了六种胰腺癌细胞系、裸鼠肿瘤异种移植模型和20个胰腺癌组织切片。ARHI在正常胰腺组织的导管和腺泡细胞中广泛表达,但在约50%的胰腺癌中下调或缺失。在五种胰腺癌细胞系中发现了ARHI基因座的异常甲基化,这些细胞系表现出ARHI表达的下调或缺失。在CpG岛I处,五种细胞系(5/5,100%)检测到高甲基化;在CpG岛II处,两种细胞系(2/5,40%)检测到高甲基化;在CpG岛III处,四种细胞系(4/5,80%)检测到高甲基化。ARHI的重新表达显著抑制了胰腺癌细胞的生长。这种抑制与细胞凋亡的诱导有关。用去甲基化剂5-氮杂-2'-脱氧胞苷(5-aza-dC)处理可恢复ARHI mRNA表达,抑制培养的PANC-1和P3人胰腺癌细胞的生长并诱导其凋亡。在无胸腺裸鼠中,5-aza-dC也抑制了PANC-1异种移植瘤的生长并诱导了凋亡,TUNEL染色观察到了这一现象。这些效应与ARHI蛋白的重新表达有关。因此,ARHI可能在相当一部分胰腺癌中作为生长抑制基因发挥作用。ARHI的重新表达显著诱导了胰腺癌细胞的凋亡。一种去甲基化剂与ARHI的重新表达共同降低了人胰腺癌细胞系的生长。